(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 0.57% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
10x Genomics's revenue in 2025 is $641,814,000.On average, 20 Wall Street analysts forecast TXG's revenue for 2025 to be $80,773,750,331, with the lowest TXG revenue forecast at $76,769,611,798, and the highest TXG revenue forecast at $84,245,100,520. On average, 20 Wall Street analysts forecast TXG's revenue for 2026 to be $77,944,024,111, with the lowest TXG revenue forecast at $73,917,106,028, and the highest TXG revenue forecast at $82,559,413,881.
In 2027, TXG is forecast to generate $84,481,754,726 in revenue, with the lowest revenue forecast at $78,443,908,662 and the highest revenue forecast at $93,398,682,699.